|Articles|October 30, 2017

The Emergence of the Few: M&A in the CRO Industry

Author(s)Craig Morgan

As the size, complexity, duration, cost, and globalization of clinical trials has grown, pharmaceutical and biotech companies have moved to outsource clinical activities to CROs to achieve a wide range of objectives.

Internal server error